OVERVIEW

AOD9604 6 mg is a synthetic peptide fragment derived from the C-terminal region (amino acids 177–191) of human growth hormone (HGH) that has been studied for its effects on fat metabolism and lipolysis. In laboratory and early clinical research, AOD9604 appeared to stimulate the breakdown of stored triglycerides in adipose tissue and inhibit the formation of new fat, acting through pathways that do not involve the classical HGH receptor or significant stimulation of U.S. Food and Drug Administration-regulated growth factors such as IGF-1. These mechanisms suggested potential benefits for fat reduction and improved metabolic flexibility without many of the hormonal side effects associated with full-length growth hormone. Experimental data in animals and small human studies reported modest fat loss and favorable safety profiles, with minimal changes in glucose regulation or hormone levels compared to placebo treatments.

Despite these early findings, AOD9604 has not been approved by major regulatory authorities for use as a weight-loss drug or therapeutic agent, and its clinical development was discontinued after mixed efficacy results in larger trials. As of 2026, it remains a research compound available primarily through laboratory suppliers for investigational studies, and products marketed for fat-burning purposes are unapproved and unregulated in many jurisdictions. Because robust evidence of meaningful weight-loss effects in humans is lacking and quality control varies outside formal research settings, individuals should avoid self-administration and seek guidance from qualified healthcare professionals when considering metabolic or obesity-related interventions.